CN102762214A - 表皮生长因子受体配体的调节 - Google Patents

表皮生长因子受体配体的调节 Download PDF

Info

Publication number
CN102762214A
CN102762214A CN2010800604035A CN201080060403A CN102762214A CN 102762214 A CN102762214 A CN 102762214A CN 2010800604035 A CN2010800604035 A CN 2010800604035A CN 201080060403 A CN201080060403 A CN 201080060403A CN 102762214 A CN102762214 A CN 102762214A
Authority
CN
China
Prior art keywords
mir
mirna
expression
egfr
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800604035A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·雷德曼
K·M·吉雷斯
F·C·卡里诺乌斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009905758A external-priority patent/AU2009905758A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of CN102762214A publication Critical patent/CN102762214A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2010800604035A 2009-11-24 2010-11-24 表皮生长因子受体配体的调节 Pending CN102762214A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009905758A AU2009905758A0 (en) 2009-11-24 Method of Modulating Epidermal Growth Factor (EGF) Ligands
AU2009905758 2009-11-24
PCT/AU2010/001577 WO2011063455A1 (en) 2009-11-24 2010-11-24 Modulation of epidermal growth factor receptor ligands

Publications (1)

Publication Number Publication Date
CN102762214A true CN102762214A (zh) 2012-10-31

Family

ID=44065735

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800604035A Pending CN102762214A (zh) 2009-11-24 2010-11-24 表皮生长因子受体配体的调节
CN2010800604001A Pending CN102762213A (zh) 2009-11-24 2010-11-24 增加对酪氨酸激酶抑制物的敏感度的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800604001A Pending CN102762213A (zh) 2009-11-24 2010-11-24 增加对酪氨酸激酶抑制物的敏感度的方法和组合物

Country Status (9)

Country Link
US (2) US20130090366A1 (enExample)
EP (2) EP2521555B1 (enExample)
JP (2) JP2013511560A (enExample)
CN (2) CN102762214A (enExample)
AU (2) AU2010324530B2 (enExample)
CA (2) CA2781571A1 (enExample)
DK (1) DK2521555T3 (enExample)
ES (1) ES2608923T3 (enExample)
WO (2) WO2011063455A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2808389A1 (en) 2004-11-12 2014-12-03 Asuragen, Inc. Methods and compositions involving MIRNA and MIRNA inhibitor molecules
WO2012005572A1 (en) * 2010-07-06 2012-01-12 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
JP6342329B2 (ja) * 2011-11-25 2018-06-13 アンテグラジャンＩｎｔｅｇｒａｇｅｎ Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法
FR2984168B1 (fr) * 2011-12-19 2019-07-05 Chanel Parfums Beaute Micro-rna pour leur utilisation dans la pigmentation
WO2013173500A2 (en) * 2012-05-15 2013-11-21 New York University Method for predicting recurrence of melanoma using mirna alterations
CN104994861B (zh) * 2012-10-18 2019-10-11 西澳大学 使用miRNA的癌症疗法
US20140308274A1 (en) * 2013-03-15 2014-10-16 Mirna Therapeutics, Inc. Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
JP2016519076A (ja) * 2013-03-15 2016-06-30 ミルナ セラピューティクス，インク． マイクロｒｎａ及びｅｇｆｒ−ｔｋｉ阻害剤を利用する癌の併用処置
EP3027225B1 (en) 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using transforming growth factor alpha
CN108537001B (zh) * 2018-04-12 2021-06-01 华中科技大学鄂州工业技术研究院 一种预测用于治疗肝癌的特异性治疗药物的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1797183B1 (en) * 2004-09-02 2012-08-01 Yale University Regulation of oncogenes by micrornas
EP2808389A1 (en) * 2004-11-12 2014-12-03 Asuragen, Inc. Methods and compositions involving MIRNA and MIRNA inhibitor molecules
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
WO2008089388A2 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025073A1 (en) * 2006-08-28 2008-03-06 The University Of Western Australia Method of modulation of expression of epidermal growth factor receptor (egfr) involving mirna

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENJAMIN KEFAS等: "microRNA-7 Inhibits the Epidermal Growth Factor Receptor and the Akt Pathway and Is Down-regulated in Glioblastoma", 《CANCER RESEARCH》 *
MICHEL ZIMMERMANN等: "The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications", 《RADIATION ONCOLOGY》 *
REBECCA J. WEBSTER等: "Regulation of Epidermal Growth Factor Receptor Signaling in Human Cancer Cells by MicroRNA-7", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
EP2504014A1 (en) 2012-10-03
AU2010324530B2 (en) 2016-12-15
WO2011063456A1 (en) 2011-06-03
JP2013511559A (ja) 2013-04-04
CA2781572A1 (en) 2011-06-03
ES2608923T3 (es) 2017-04-17
CN102762213A (zh) 2012-10-31
US20130090366A1 (en) 2013-04-11
EP2521555B1 (en) 2016-09-28
JP2013511560A (ja) 2013-04-04
AU2010324530A1 (en) 2012-07-19
US9051551B2 (en) 2015-06-09
EP2504014A4 (en) 2013-04-17
WO2011063455A1 (en) 2011-06-03
US20130116299A1 (en) 2013-05-09
AU2010324529A1 (en) 2012-07-19
EP2521555A1 (en) 2012-11-14
EP2521555A4 (en) 2013-08-07
DK2521555T3 (en) 2017-01-09
CA2781571A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
CN102762214A (zh) 表皮生长因子受体配体的调节
US9944932B2 (en) MiRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT
US9675633B2 (en) miRNA for treating cancer and for use with adoptive immunotherapies
JP2019512489A (ja) マイクロｒｎａおよびその使用方法
US10174314B2 (en) MiRNA for treating head and neck cancer
US11364258B2 (en) Methods for treating chondrosarcoma using microrna(miR)
CN111566212A (zh) miRNA分子，等同物，安塔够妙或其来源用于治疗和/或诊断与神经元缺陷相关的病症和/或疾病或用于神经元生成和/或再生
CA2889020A1 (en) Treatment of metastatic breast cancer
ES2764699T3 (es) Molécula de miARN definida por su fuente y sus usos diagnósticos y terapéuticos en enfermedades o afecciones asociadas a la TEM
WO2022081693A1 (en) Compositions and methods targeting circ2082 for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121031